Sonova (OTCPK:SONV.F) Update / briefing March 23, 2026 09:00 AM ET Company ParticipantsAnders Rosengren - Group VP of Research and DevelopmentDavid Adlington - Managing DirectorElodie Carr-Cingari - CFOEric Bernard - Former CEOGraham Doyle - Executive Director of Equity ResearchHassan Al-Wakeel - Managing Director and Head of European MedTech & Services ResearchHenrietta Rumberger - ReporterJulien Ouaddour - Executive Director of Equity ResearchRoberto di Fiore - Group VP and COOThomas Bernhardsgrütter - He ...

TransAlta (NYSE:TAC) 2026 Investor Day March 23, 2026 09:00 AM ET Company ParticipantsBen Harris - Manager of Investor RelationsBen Pham - Managing DirectorChris Fralick - EVP of GenerationJoel Hunter - EVP of Finance and CFOJohn Kousinioris - President and CEOJohn Mould - Managing DirectorMark Jarvi - Managing DirectorMaurice Choy - Managing DirectorRobert Hope - Managing DirectorStephanie Paris - VP of Investor Relations and Corporate StrategyStephanie ParisGood morning, everyone and welcome to TransAlta' ...

FY and Q4 2025 Results Presentation Disclaimer and Forward-Looking Statements This presentation has been prepared solely for information and does not purport to contain all of the information that may be necessary or desirable to fully and accurately evaluate Caledonia Mining Corporation Plc ("Caledonia" or "the Company") or its business prospects. For the purposes of this notice, "presentation" includes this document, any oral presentation, any questions and answer session and any written or oral material ...

BioLineRx (NasdaqCM:BLRX) Q4 2025 Earnings call March 23, 2026 08:30 AM ET Company ParticipantsElla Sorani - Chief Development OfficerIrina Koffler - Investor Relations OfficerMali Zeevi - CFOPhilip Serlin - CEOConference Call ParticipantsJoe Pantginis - Managing Director and Equity Research AnalystJohn Vandermosten - Senior AnalystJustin Walsh - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the BioLineRx fourth quarter and full year 2025 financial results conference call. All p ...

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue to the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28][29] Question: Enthusiasm from principal investigators for GLIX1 trial - There is significant enthusiasm from investigators regarding GLIX1's novel mechanism of action and preclinical results, with eagerness to initiate the study [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway, but no interim readouts expected due to the study's blinded nature [44][46] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients, typically having exhausted standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [18] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [19] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [20] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [20] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][20] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [12] - The company continues to support the development of motixafortide in pancreatic cancer, with a phase IIb clinical trial showing accelerated enrollment [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU [8] - The unmet need in glioblastoma treatment is significant, with current therapies showing limited advancements since 2005 [7] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma and other cancers, highlighting the enthusiasm from clinical investigators [38] - The company is well-positioned to drive innovation in challenging cancer types and is focused on maximizing the value of GLIX1 [56] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [16] - The company remains a lean organization following the shutdown of U.S. commercialization operations, concentrating on development [12] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [27][28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism and promising preclinical results [38] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the study are recurrent or progressed GBM patients, having run out of standard care options [46] Question: Measurement of blood-brain barrier penetration in the study - While biopsies may be taken, the study is not designed to assess blood-brain barrier penetration as a primary measure [50] Question: Ayrmid's guidance on expected sales - Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [51]

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) H2 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsDing Nanchao - Deputy General Manager and Chief Marketing OfficerGe Junyou - President and CEOJinbo Zhang - Director of the Analytical DepartmentMatthew Culley - Portfolio ManagerWei Chen - Deputy General Manager and VP of Molecule R&DXiangyang Tan - Chief Scientific OfficerXiao Ping Jin - Chief Medical OfficerZe Jian Zhou - CFOConference Call ParticipantsShen Ziyi - Equity Research Anal ...

Delivery Hero Taiwan Divestment Conference Call Summary Company Overview - **Company**: Delivery Hero (OTCPK:DELH.Y) - **Event**: Taiwan Divestment Conference Call - **Date**: March 23, 2026 Key Points Industry and Company Context - Delivery Hero is undergoing a strategic review, with the divestment of its food delivery operations in Taiwan to Grab for **$600 million** in cash, marking a significant milestone in its strategy [3][2] - The Taiwan business generated a **GMV of EUR 1.5 billion** in full year 2025, accounting for approximately **3%** of the group's total GMV [5] Financial Implications - The divestment will reduce Delivery Hero's net leverage from approximately **2.7 times to 2.2 times**, strengthening its capital structure [5] - The transaction is expected to close in the **second half of 2026**, pending regulatory approvals [5] - Delivery Hero will provide support services for a migration period of up to **12 months** post-transaction [5] Operational Performance - The Taiwan business was noted to have a positive EBITDA before central costs, with the impact of its loss on overall EBITDA expected to be marginal for 2026 [14] - The company anticipates that the transition services will not significantly affect cash flow or EBITDA during the support period [14] Market Position and Competitiveness - Delivery Hero holds a strong market position in Taiwan, having improved profitability over recent years [32] - The competitive landscape includes Uber, with varying strengths in different geographical areas [32] Strategic Rationale - The divestment is part of a broader strategy to optimize the company's asset portfolio and focus on core operations [3] - The management emphasized the importance of maintaining flexibility and being prepared for future opportunities or challenges [10] Future Outlook - The company is not providing interim updates on other ongoing reviews to protect the integrity of the processes [5] - The management expressed confidence in the deal's value for both Delivery Hero and Grab, indicating a favorable market environment for the transaction [24] Additional Insights - The issuance of a **$1.4 billion** term loan prior to the divestment raised questions among investors regarding the need for such a substantial cash balance [8] - The management clarified that the term loan was aimed at repaying existing debt and strengthening the capital structure [10] This summary encapsulates the critical aspects of the Delivery Hero conference call, highlighting the strategic divestment, financial implications, operational performance, and market positioning within the food delivery industry.

WeRide (NasdaqGM:WRD) Q4 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsJennifer Li - CFO and Head of InternationalTony Han - Founder, Chairman, and CEONone - Company RepresentativeConference Call ParticipantsFang Xinyu - Associate AnalystJiajie Shen - Equity Research AnalystLeo You - Research AnalystMing-Hsun Lee - Equity Research AnalystTim Hsiao - Equity AnalystOperatorGood morning and good evening, ladies and gentlemen. Thank you for standing by, and welcome to WeRide's Q4 and Full Ye ...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) H2 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsDing Nanchao - Deputy General Manager and Chief Marketing OfficerGe Junyou - President and CEOJinbo Zhang - Director of the Analytical DepartmentMatthew Culley - Portfolio ManagerWei Chen - Deputy General Manager and VP of Molecule R&DXiangyang Tan - Chief Scientific OfficerXiao Ping Jin - Chief Medical OfficerZe Jian Zhou - CFOConference Call ParticipantsShen Ziyi - Equity Research Anal ...